PT1587821E - Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina - Google Patents

Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina Download PDF

Info

Publication number
PT1587821E
PT1587821E PT03813782T PT03813782T PT1587821E PT 1587821 E PT1587821 E PT 1587821E PT 03813782 T PT03813782 T PT 03813782T PT 03813782 T PT03813782 T PT 03813782T PT 1587821 E PT1587821 E PT 1587821E
Authority
PT
Portugal
Prior art keywords
transthyretin
misfolding
methods
inhibiting
compositions
Prior art date
Application number
PT03813782T
Other languages
English (en)
Inventor
Jeffrey W Kelly
Evan T Powers
Hossein Razavi
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1587821(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT1587821E publication Critical patent/PT1587821E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
PT03813782T 2002-12-19 2003-12-19 Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina PT1587821E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43507902P 2002-12-19 2002-12-19
US46543503P 2003-04-24 2003-04-24

Publications (1)

Publication Number Publication Date
PT1587821E true PT1587821E (pt) 2008-09-23

Family

ID=32685364

Family Applications (2)

Application Number Title Priority Date Filing Date
PT08014241T PT1988397E (pt) 2002-12-19 2003-12-19 Composições e utilizações para estabilização da transtirretina e inibição do enrolamento
PT03813782T PT1587821E (pt) 2002-12-19 2003-12-19 Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT08014241T PT1988397E (pt) 2002-12-19 2003-12-19 Composições e utilizações para estabilização da transtirretina e inibição do enrolamento

Country Status (19)

Country Link
US (6) US7214695B2 (pt)
EP (3) EP1988397B8 (pt)
JP (3) JP4665076B2 (pt)
KR (1) KR101089904B1 (pt)
CN (2) CN101413143B (pt)
AT (2) ATE405840T1 (pt)
AU (2) AU2003303196C1 (pt)
BE (1) BE2012C008I2 (pt)
BR (1) BRPI0317463B8 (pt)
CA (2) CA2800237C (pt)
CY (2) CY1108467T1 (pt)
DE (2) DE60323155D1 (pt)
DK (2) DK1587821T3 (pt)
ES (3) ES2524803T3 (pt)
FR (1) FR12C0008I2 (pt)
LU (1) LU91935I2 (pt)
PT (2) PT1988397E (pt)
SI (1) SI1587821T1 (pt)
WO (1) WO2004056315A2 (pt)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
PT1988397E (pt) * 2002-12-19 2011-12-02 Scripps Research Inst Composições e utilizações para estabilização da transtirretina e inibição do enrolamento
ES2398838T3 (es) * 2004-03-12 2013-03-22 Biodel, Inc. Composiciones de suministro de fármacos de acción rápida
MXPA06013381A (es) * 2004-05-20 2007-03-01 Scripps Research Inst Estabilizacion de transtiretina.
ES2369919T3 (es) * 2004-08-26 2011-12-09 Biocrine Ab Métodos y compuestos para tratar la diabetes.
WO2007022138A2 (en) * 2005-08-11 2007-02-22 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2010054127A1 (en) * 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010091253A1 (en) 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
BR112012026803A2 (pt) 2010-04-21 2016-07-12 Chiesi Farma Spa composto
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
SI3191461T1 (sl) * 2014-09-08 2022-01-31 Pfizer Inc. Kristalinske trdne oblike 6-karboksi-2-(3,5-diklorofenil)-benzoksazola
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107344927A (zh) 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
CN106496014A (zh) * 2016-10-17 2017-03-15 河北美星化工有限公司 一种二氟尼柳的制备方法
EP3630153A2 (en) 2017-05-22 2020-04-08 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108558599B (zh) * 2018-03-29 2021-01-29 浦拉司科技（上海）有限责任公司 2-联苯基甲醇的合成工艺
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
EP3953339A1 (en) * 2019-04-11 2022-02-16 Inke, S.A. Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
WO2020232325A1 (en) 2019-05-16 2020-11-19 Teva Pharmaceuticals International Gmbh Solid state forms of tafamidis and salts thereof
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021093809A1 (zh) 2019-11-15 2021-05-20 苏州科睿思制药有限公司 他发米帝司的晶型及其制备方法和用途
KR20220114626A (ko) 2019-12-20 2022-08-17 화이자 아일랜드 파마슈티컬즈 6-카르복시 벤족사졸 유도체의 효율적인 제조 방법
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
EP4097092A1 (en) 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112683844A (zh) * 2020-12-07 2021-04-20 东华理工大学 一种振动对吲哚美辛-糖精共晶形成影响的研究方法
CN112858690B (zh) * 2021-01-21 2023-11-10 宁波职业技术学院 一种尿白蛋白/尿肌酐复合质控品及其制备方法
CN114907283A (zh) * 2021-02-07 2022-08-16 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
CN113372290A (zh) * 2021-05-21 2021-09-10 遵义医科大学 一种药物Tafamidis的合成方法
CN113321627B (zh) * 2021-06-06 2022-05-24 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
AR126070A1 (es) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
WO2024023710A1 (en) 2022-07-28 2024-02-01 Pfizer Inc. Tafamidis pharmaceutical compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435079A (en) 1890-08-26 Lock-nut for axles
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) * 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) * 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
JP3021028B2 (ja) 1990-11-19 2000-03-15 株式会社日本化学工業所 アゾール型カチオン染料
CH681806A5 (pt) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (ja) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd 芳香族化合物とその製造方法
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0673050A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ヘテロ環化合物
JPH0673051A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ベンズアゾール誘導体
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH06239849A (ja) 1993-02-16 1994-08-30 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置
JP3243887B2 (ja) 1993-05-28 2002-01-07 三菱化学株式会社 有機電界発光素子
JPH0797379A (ja) 1993-09-06 1995-04-11 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
JP3861930B2 (ja) 1995-12-15 2006-12-27 ソニー株式会社 金属複核錯体、その製造方法及び光学的素子
JPH09227576A (ja) 1996-02-23 1997-09-02 Sony Corp 金属複核錯体、その製造方法及び光学的素子
JP3760508B2 (ja) 1996-06-10 2006-03-29 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子
WO1997047319A1 (en) 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
EP1053237B1 (en) 1998-02-04 2003-07-02 The Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6107491A (en) 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (ja) 1998-09-22 2000-04-07 Toray Ind Inc 発光素子
JP2001055332A (ja) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
JP2003502408A (ja) 1999-06-18 2003-01-21 バイエル アクチェンゲゼルシャフト フェノキシフルオロピリミジン類
JP2001064166A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 貼付剤
JP2001064205A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 製剤組成物
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
PL207869B1 (pl) 2000-03-16 2011-02-28 Hoffmann La Roche Pochodne kwasu karboksylowego, środek farmaceutyczny i sposób wytwarzania pochodnych kwasu karboksylowego
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (ja) 2000-04-10 2007-07-18 三菱化学株式会社 有機電界発光素子
JP2001301329A (ja) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp 光学記録媒体
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
AU2001286702B2 (en) 2000-08-24 2008-03-13 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
EP1330432A2 (en) 2000-11-04 2003-07-30 Aventis Pharma Limited Substituted alkanoic acids
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
US7253154B2 (en) 2001-11-16 2007-08-07 Nippon Chemiphar Co., Ltd. Substituted thiazolopyrimidines as xanthine oxidase inhibitors
AU2002353739A1 (en) 2001-11-28 2003-06-10 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1465854A4 (en) 2001-12-19 2005-06-08 Atherogenics Inc CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
WO2003080545A2 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
PT1988397E (pt) * 2002-12-19 2011-12-02 Scripps Research Inst Composições e utilizações para estabilização da transtirretina e inibição do enrolamento
US7332516B2 (en) 2003-01-14 2008-02-19 Merck + Co., Inc. Geminally di-substituted NSAID derivatives as Aβ42 lowering agents
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
JP2004302049A (ja) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd 感光性樹脂組成物
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2004094395A2 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA06013381A (es) * 2004-05-20 2007-03-01 Scripps Research Inst Estabilizacion de transtiretina.

Also Published As

Publication number Publication date
CA2800237A1 (en) 2004-07-08
JP2013256521A (ja) 2013-12-26
DE122012000007I1 (de) 2012-04-12
CA2800237C (en) 2016-05-17
LU91935I9 (pt) 2019-01-04
DE60323155D1 (de) 2008-10-02
EP1587821A2 (en) 2005-10-26
FR12C0008I2 (fr) 2013-01-11
PT1988397E (pt) 2011-12-02
ES2312857T3 (es) 2009-03-01
US8653119B2 (en) 2014-02-18
DK1587821T3 (da) 2008-11-10
US7214695B2 (en) 2007-05-08
BRPI0317463B1 (pt) 2017-04-18
SI1587821T1 (sl) 2009-02-28
AU2010201263A1 (en) 2010-04-22
JP2010270134A (ja) 2010-12-02
WO2004056315A8 (en) 2005-12-08
JP5756151B2 (ja) 2015-07-29
US8168663B2 (en) 2012-05-01
CN100448852C (zh) 2009-01-07
AU2003303196A1 (en) 2004-07-14
EP1988397B8 (en) 2012-02-15
WO2004056315A2 (en) 2004-07-08
US20120065237A1 (en) 2012-03-15
BR0317463A (pt) 2005-11-16
CN101413143A (zh) 2009-04-22
KR20050090410A (ko) 2005-09-13
AU2003303196B2 (en) 2010-03-25
AU2010201263B8 (en) 2013-04-18
EP1587821A4 (en) 2007-05-09
US7214696B2 (en) 2007-05-08
ES2524803T3 (es) 2014-12-12
EP2325651A2 (en) 2011-05-25
CY1108467T1 (el) 2014-04-09
BRPI0317463B8 (pt) 2021-05-25
CN101413143B (zh) 2013-09-18
EP1587821B1 (en) 2008-08-20
CY2012005I1 (el) 2015-10-07
US20100120919A1 (en) 2010-05-13
AU2010201263B2 (en) 2012-12-20
FR12C0008I1 (pt) 2012-03-30
US20140134753A1 (en) 2014-05-15
CY2012005I2 (el) 2015-10-07
EP2325651B1 (en) 2014-10-08
US20070078186A1 (en) 2007-04-05
ATE524741T1 (de) 2011-09-15
LU91935I2 (fr) 2012-03-26
CA2510455A1 (en) 2004-07-08
US7560488B2 (en) 2009-07-14
JP4665076B2 (ja) 2011-04-06
ES2373639T3 (es) 2012-02-07
AU2003303196C1 (en) 2021-03-25
EP2325651A3 (en) 2011-09-21
DK1988397T3 (da) 2011-12-12
AU2010201263A8 (en) 2013-04-18
US20040152140A1 (en) 2004-08-05
ATE405840T1 (de) 2008-09-15
US20060057644A1 (en) 2006-03-16
CN1747965A (zh) 2006-03-15
JP2006511612A (ja) 2006-04-06
EP1988397B1 (en) 2011-09-14
WO2004056315A3 (en) 2005-08-11
BE2012C008I2 (pt) 2023-03-07
CA2510455C (en) 2013-03-12
KR101089904B1 (ko) 2011-12-05
EP1988397A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
EP1587821A4 (en) COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETINE AND FOR INHIBITING TRANSTHYRETINE MALFUNCTION
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
IL163911A0 (en) Naltrexone hydrochloride compositions
GB0318447D0 (en) Therapeutic agents
MXPA04002931A (es) Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad.
IS6950A (is) Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ZA200709535B (en) Methods and compositions for the treatment of CNS-related conditions
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EP2065366A3 (en) HIF hydroxylase inhibitors
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05013251A (es) Composiciones para estado de oxigeno mejorado en animales de compania.
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing
WO2007025092A3 (en) Stabilized and preserved ketotifen ophthalmic compositions
AU2003260723A1 (en) Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
BR0214244A (pt) Uso de uma ascomicina
DE60305520D1 (de) 2" oxo-voruscharin und derivaten